VTRS · 8-K · 20260806PR000037

Revenue Performance and Mix

Viatris Inc · 2026-08-06 · Importance 31 · Surprise 32 · From source text

Second-quarter total revenues increased 3.5% operationally, driven primarily by new product sales in Developed Markets and strong growth in Greater China. Greater China net sales rose 16% operationally to $685.2 million, while Developed Markets increased 2% operationally to $2.16 billion. Emerging Markets declined 2% operationally to $544.4 million, and JANZ was flat operationally at $304.2 million. Brands grew 4% operationally, supported by continued strength in Greater China and Emerging Markets, while Generics grew 3% operationally but were partially offset by ARV supply constraints in Emerging Markets.

Key facts

• Greater China net sales for Q2 2026: $713.8 million, up 21% reported and 16% operational versus Q2 2025 source
• Total Net Sales for Q2 2026: $3,745.9 million, up 5% reported and 4% operational versus Q2 2025 source
• Developed Markets net sales for Q2 2026: $2,193.7 million, up 4% reported and 2% operational versus Q2 2025 source
• Brands net sales for Q2 2026: $2,418.4 million, up 6% reported and 4% operational versus Q2 2025 source
• Generics net sales for Q2 2026: $1,327.5 million, up 3% reported and 3% operational versus Q2 2025 source
• Total Revenues for Q2 2026: $3,756.8 million, representing 5% reported growth compared to Q2 2025 source
• Total Revenues were up 3.5% operationally compared to second-quarter 2025 source

Impact estimates